I was reminded of the issue recently when a physician colleague of mine treated an elderly man who presented with signs and ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Joseph Thomas, MD, MBA, Fellow of Metabolic and Nutritional Medicine In collaboration with Oxygen Health Systems Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results